Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/phar.2467 http://scihub22266oqcxt.onion/10.1002/phar.2467 33044019!7675747!33044019     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacotherapy 2020 ; 40 (11): 1072-1081 Nephropedia Template TP {{tp|p=33044019|t=2020. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality |pdf=|usr=}}{{33044019}} gab.com Text Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality JO: Pharmacotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33044019 #FOAvip INTRODUCTION: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial. OBJECTIVES: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up. METHODS: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded. RESULTS: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages +/- SD were 62.3 +/- 15.9 years (53.7% male) and 61.9 +/- 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7). CONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ. Twit Text FOAVip Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality ????Pharmacotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33044019 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33044019 #FOAvip English Wikipedia <ref>{{Cite pmid|33044019}}</ref> Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality #MMPMID33044019 Annie FH; Sirbu C; Frazier KR; Broce M; Lucas BD Jr Pharmacotherapy 2020[Nov]; 40 (11): 1072-1081 PMID33044019show ga INTRODUCTION: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial. OBJECTIVES: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up. METHODS: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded. RESULTS: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages +/- SD were 62.3 +/- 15.9 years (53.7% male) and 61.9 +/- 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7). CONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |*Off-Label Use[MESH] |Aged[MESH] |COVID-19/*mortality[MESH] |Clinical Trials as Topic[MESH] |Cohort Studies[MESH] |Databases, Factual[MESH] |Female[MESH] |Hospitalization/*statistics & numerical data[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage/adverse effects/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Mortality/trends[MESH] |Retrospective Studies[MESH]Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World (epmc).pdf DeepDyve Pubget Overpricing